As I indicated in an earlier post, the volume makes it clear that institutions have been on both sides of numerous recent trades. It is not only important to see who new buyers are, but to be sure old holders are still with us. The most significant positive sign would be if some major holders took advantage of the price break to add to their holdings. These folks know us the best, and renewed buying would be a welcome sign of confidence. MARK
With this kind of volume it is clear that institution are both buying and selling. Therefore, it will be interesting to note who has been doing the buying and conversely the selling. Hopefully, our largest holders, those who know us best, have taken this opportunity to add to their positions. We will see. Patience may be a virtue, but eventually institutions must see the clouds part and a bit of sunshine begin to come through. This next conference call is vital and must give more then vague promises. A firm timeline on all phase three products would be helpful, as would any word on 214 complete responses. Also, the company view on Movantik sales and pain drug progress would be helpful. MARK
I could not agree more. Some hard numbers on the newly approved drugs, a true update on 214, where exactly we are on the pain drugs and Cipro and intelligent timelines for all phase three products. Both individual investors and institutions need significantly better clarity at this point. It is truly time to put our cards on the table.
I also have held the stock for a long period, but my perspective is somewhat different. The stock is aggressive. People buy it for future gains as opposed to current numbers. As such, when the market is weak we get hit harder. I hope that I am right, but expect to find out a lot more on the next conference call. If you and I are upset, think what they are hearing from the institutional holders. Hopefully, the conference call this quarter will give us some fundamental and positive results both on the pipeline products and the partnered ones. Good luck to the longs.
In the recent release on 214, the piece indicated that phase one would have about 20 patients. A recent writer indicated that MDA had suggested the number was 100. Any ideas as to why we can't get the number of patients straight? MARK
I need some help here. Can someone tell me when Bayer expects to end phase 3? Basically, I'm looking for some kind of timetable as to when the drug might be approved and if that comes about, what king of earnings impact it might have on us. Thanks, and good luck to all longs. I think our time is coming sooner then most expect.
OK guys, please help me out here. Klaus, are you saying that the disease was cured, or that the patient is surviving. If cured that would be spectacular. If surviving, that would be less significant as the study has only just begun. Also, how did you discern that the chart related to the human tests and not the previous animal study. Thanx, MARK
Actually they did. More in depth numbers on Movantik, and a better time horizon on pain meds and 214. Also, the explanation of why 214 is so different from current competitors was clearer and more understandable then what I have heard before. Unfortunately 214 and the pain meds still seem several years away. MARK
something positive to come out of tomorrows conference. Most often these things are fairly bland. However, some positive and newsworthy comments on 214, Movantik, 102 or the pain meds would be most helpful in this environment. MARK
Klaus, it is not clear who you are quoting on the "we expect" line for global sales. If those numbers are accurate, it suggests great ongoing numbers for Movantik, and by extension for us. Please clarify where the data is from, and thanks for the helpful data. MARK
Regarding 214, I am wondering if any reasonable number of patients have a complete response result, would that constitute significant information and thereby require a general release. My logic is that with everyone from the patient to their doctors, researchers friends etc. knowing these results, can secrecy be maintained/? M.
As an owner of this stock for a number of years you can well understand my enthusiasm about the recent stock action. Whether Movantik is selling better then anticipated, the BXLT deal is seen as highly enticing or 214 is looming large, I don't know. Maybe it is a combo of all of them. Plus we have the pain drug and a possible deal on 102. Again after years of waiting, I'm thinking that the quality of the science is finally shining through. Although 214 sure looks promising, it would be helpful to keep us up to date if the super exciting events begin happening. In the early animal tests some of those treated were free of cancer in a week or less. If such a thing happened in the human tests, that would be major news and hopefully would be shared promptly. Anyway, good luck to the longs, and a happy healthy and prosperous New Year to you and yours. MARK
Pfizer making a bid would not surprise me. However, as a long term holder I would not be interested at even double these levels. Let's wait for the stock to go into the 20's next year and then hope for a multiple of those numbers. MARK